Skip to content

‘They Lied’: Abbott, FDA Formula Deal Stirs Democrat’s Ire

  • Agency hasn’t addressed whistle-blower’s claims, DeLauro says
  • Abbott says there’s no link between its formula, infections
Rosa DeLauro
Rosa DeLauroPhotographer: Ting Shen/Bloomberg
Updated on

A leading House lawmaker clashed in a hearing with the Food and Drug Administration’s chief over plans to reopen an Abbott Laboratories infant formula plant without first addressing a whistle-blower’s allegations.  

House Appropriations Chairwoman Rosa DeLauro said she wants to know why FDA Commissioner Robert Califf entered an agreement that will allow formula production to resume at Abbott’s plant in Sturgis, Michigan. While Abbott is facing fallout from sickness in four babies given infant formula in recent months, DeLauro is concerned that the agency hasn’t dealt with the whistle-blower’s claims of earlier quality lapses and falsified records at the plant.